Difgen Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.00 Cr
as on 05-11-2024
- Paid Up Capital ₹ 1.00 Cr
as on 05-11-2024
- Company Age 2 Year, 7 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 5.09 M
as on 05-11-2024
About Difgen Pharmaceuticals
The Company is engaged in the Research & Development Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 Cr and a paid-up capital of Rs 1.00 Cr.
The company currently has active open charges totaling ₹5.09 M.
Srinivasan Vedantham, Vijay Vasireddy, Amol Walke, and Six other members serve as directors at the Company.
- CIN/LLPIN
U24230TG2022PTC162383
- Company No.
162383
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
06 May 2022
- Date of AGM
15 Nov 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- Location
Hyderabad, Telangana, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Difgen Pharmaceuticals?
Board Members(9)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Vijay Vasireddy  | Director | 04-Nov-2022 | Current |
Srinivasan Vedantham  | Director | 06-May-2022 | Current |
| Amol Walke | Director | 04-Jul-2022 | Current |
| Yatin Desai | Director | 24-May-2022 | Current |
| Punit Thakrar | Director | 04-Jul-2022 | Current |
| Zubin Gandhi | Director | 24-May-2022 | Current |
Financial Performance and Corporate Structure Insights of Difgen Pharmaceuticals.
Difgen Pharmaceuticals Private Limited, for the financial year ended 2023, experienced no change in revenue, with a 0% increase. The company also saw a no change in profitability, with a 0% increase in profit. The company's net worth witnessed no change by increase of 0%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets | |||||||
| Profit or Loss | |||||||
| Net Worth | |||||||
| EBITDA |
What is the Ownership and Shareholding Structure of Difgen Pharmaceuticals?
In 2023, Difgen Pharmaceuticals had a promoter holding of 80.00% and a public holding of 20.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Esteem Industries Private Limited
Active 22 years 11 monthsAmol Walke and Zubin Gandhi are mutual person
Orizo Pharma Private Limited
Active 2 years 11 monthsAmol Walke, Yatin Desai and 2 more are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Hdfc Bank Limited Creation Date: 28 May 2024 | ₹2.69 M | Open |
Hdfc Bank Limited Creation Date: 25 Jul 2022 | ₹2.41 M | Open |
How Many Employees Work at Difgen Pharmaceuticals?
Difgen Pharmaceuticals has a workforce of 92 employees as of Apr 03, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Difgen Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Difgen Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
